ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VRTX Vertex Pharmaceuticals Inc

401.08
0.92 (0.23%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vertex Pharmaceuticals Inc NASDAQ:VRTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.92 0.23% 401.08 371.34 408.70 405.665 397.59 401.50 1,063,962 05:00:08

Vertex to Announce Second Quarter 2022 Financial Results on August 4

18/07/2022 9:05pm

Business Wire


Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Vertex Pharmaceuticals Charts.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2022 Earnings Call”.

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 12 consecutive years on Science magazine's Top Employers list and one of the 2021 Seramount (formerly Working Mother Media) 100 Best Companies. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

Source: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Investors: Manisha Pai, 617-961-1899 Miroslava Minkova, 617-341-6135

1 Year Vertex Pharmaceuticals Chart

1 Year Vertex Pharmaceuticals Chart

1 Month Vertex Pharmaceuticals Chart

1 Month Vertex Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock